Antiplasmodial efficacy of 2,4--diaminopyrimidine0sylfonamide combinations, especially against chloroquine-resistant malaria.
This presentation deals with the historical development of the antifolate pyrimidines and related compounds, first as antimalarial substances and later as potent antibacterial agents. It describes the first quantitation of the combined action, through sequential blockade, of the substances with sulfonamides, and outlines the usefulness of the combinations in the therapy of normally sensitive and multiresistant strains of Plasmodium falciparum.
D000962:Antimalarials / Q000266:history*; D002738:Chloroquine / Q000627:therapeutic use; D004338:Drug Combinations / Q000266:history; D004353:Drug Evaluation, Preclinical / Q000266:history; D004352:Drug Resistance, Microbial; D013293:Enterococcus faecalis / Q000187:drug effects; D005492:Folic Acid / Q000096:biosynthesis; D005493:Folic Acid Antagonists; D049673:History, 20th Century; D006801:Humans; D007780:Lacticaseibacillus casei / Q000187:drug effects; D002955:Leucovorin / Q000096:biosynthesis; D008288:Malaria / Q000188:drug therapy*; D008826:Microbial Sensitivity Tests; D010963:Plasmodium falciparum / Q000187:drug effects*; D011739:Pyrimethamine / Q000266:history / Q000494:pharmacology; D011743:Pyrimidines / Q000266:history* / Q000627:therapeutic use*; D013415:Sulfalene / Q000627:therapeutic use; D013449:Sulfonamides / Q000266:history* / Q000627:therapeutic use; D014295:Trimethoprim / Q000266:history / Q000494:pharmacology / Q000627:therapeutic use
D000962:Antimalarials; D004338:Drug Combinations; D005493:Folic Acid Antagonists; D011743:Pyrimidines; D013449:Sulfonamides; D002738:Chloroquine; D005492:Folic Acid; D014295:Trimethoprim; D002955:Leucovorin; D013415:Sulfalene; D011739:Pyrimethamine